NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Ou, your description of the AMGEN trial is inaccurate IMHO.

Please see: https://clinicaltrials.gov/ct2/show/NCT01575873

Note: IMO, they shared topline results at the 12 month mark for primary and secondary 12 month evaluation, and they continued the blind thereafter for another 12 months to get to the additional secondary 24 month analysis.

Also See:

Evaluation of the primary endpoint (the percent change from baseline in lumbar spine BMD at 12 months, assessing non-inferiority) and two secondary endpoints assessed at 12 months (the percent change from baseline in lumbar spine and total hip BMD, assessing superiority) was conducted; further analysis of these results is ongoing and will be submitted to a future medical conference and for publication. The study remains double-blinded and ongoing for an additional 12 months.